NO328628B1 - Fremgangsmate for syntetisering av camptothecin relaterte forbindelser - Google Patents

Fremgangsmate for syntetisering av camptothecin relaterte forbindelser Download PDF

Info

Publication number: NO328628B1
Authority: NO; Norway
Prior art keywords: compound; mixture; reagent; accordance; stirring
Prior art date: 2001-02-21

Application number

NO20033579A

Other languages

English (en)

Norwegian (no)

Other versions

NO20033579L (no

NO20033579D0 (no

Inventor

Takanori Ogawa

Hiroyuki Nishiyama

Miyuki Uchida

Seigo Sawada

Original Assignee

Yakult Honsha Kk

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-21

Filing date

2003-08-13

Publication date

2010-04-12

2003-08-13 Application filed by Yakult Honsha Kk filed Critical Yakult Honsha Kk

2003-08-13 Publication of NO20033579D0 publication Critical patent/NO20033579D0/no

2003-10-10 Publication of NO20033579L publication Critical patent/NO20033579L/no

2010-04-12 Publication of NO328628B1 publication Critical patent/NO328628B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 201
238000000034 method Methods 0.000 title claims description 35
230000002194 synthesizing effect Effects 0.000 title description 4
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 title 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title 1
229940127093 camptothecin Drugs 0.000 title 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 title 1
239000000203 mixture Substances 0.000 claims description 36
238000006243 chemical reaction Methods 0.000 claims description 26
239000002904 solvent Substances 0.000 claims description 26
238000003756 stirring Methods 0.000 claims description 25
NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 claims description 24
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 23
239000007818 Grignard reagent Substances 0.000 claims description 17
150000004795 grignard reagents Chemical class 0.000 claims description 17
HHCZNCHGYNRIBP-UHFFFAOYSA-N 1-(2-amino-5-hydroxyphenyl)propan-1-one Chemical compound CCC(=O)C1=CC(O)=CC=C1N HHCZNCHGYNRIBP-UHFFFAOYSA-N 0.000 claims description 16
230000001590 oxidative effect Effects 0.000 claims description 15
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
238000010531 catalytic reduction reaction Methods 0.000 claims description 13
125000006239 protecting group Chemical group 0.000 claims description 13
RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 claims description 12
239000003153 chemical reaction reagent Substances 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 11
239000012298 atmosphere Substances 0.000 claims description 10
238000002156 mixing Methods 0.000 claims description 8
239000003810 Jones reagent Substances 0.000 claims description 7
239000005708 Sodium hypochlorite Substances 0.000 claims description 7
239000011261 inert gas Substances 0.000 claims description 7
238000005574 benzylation reaction Methods 0.000 claims description 5
GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 4
238000010992 reflux Methods 0.000 claims description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 41
239000000243 solution Substances 0.000 description 32
230000015572 biosynthetic process Effects 0.000 description 30
238000003786 synthesis reaction Methods 0.000 description 27
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
239000007864 aqueous solution Substances 0.000 description 14
238000004128 high performance liquid chromatography Methods 0.000 description 14
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 13
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
239000012300 argon atmosphere Substances 0.000 description 12
229920006395 saturated elastomer Polymers 0.000 description 11
239000007787 solid Substances 0.000 description 11
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 8
229940073608 benzyl chloride Drugs 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
239000000463 material Substances 0.000 description 8
238000005160 1H NMR spectroscopy Methods 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 7
239000007858 starting material Substances 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000007795 chemical reaction product Substances 0.000 description 6
239000000543 intermediate Substances 0.000 description 6
239000012044 organic layer Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
229910052938 sodium sulfate Inorganic materials 0.000 description 6
235000011152 sodium sulphate Nutrition 0.000 description 6
238000006257 total synthesis reaction Methods 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
-1 aryl isonitrile Chemical class 0.000 description 5
150000002576 ketones Chemical class 0.000 description 5
UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 5
229910000027 potassium carbonate Inorganic materials 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
238000010898 silica gel chromatography Methods 0.000 description 5
239000011343 solid material Substances 0.000 description 5
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
235000019270 ammonium chloride Nutrition 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
239000007810 chemical reaction solvent Substances 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000002451 electron ionisation mass spectrometry Methods 0.000 description 4
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
230000000704 physical effect Effects 0.000 description 4
230000035484 reaction time Effects 0.000 description 4
238000005406 washing Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
239000006227 byproduct Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
XLYPHUGUKGMURE-UHFFFAOYSA-N 5-hydroxy-2-nitrobenzaldehyde Chemical compound OC1=CC=C([N+]([O-])=O)C(C=O)=C1 XLYPHUGUKGMURE-UHFFFAOYSA-N 0.000 description 2
238000006646 Dess-Martin oxidation reaction Methods 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
238000007605 air drying Methods 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000002198 insoluble material Substances 0.000 description 2
239000013067 intermediate product Substances 0.000 description 2
229960000779 irinotecan hydrochloride Drugs 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
239000012286 potassium permanganate Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000007154 radical cyclization reaction Methods 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
238000007363 ring formation reaction Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 1
LILVVZJBGYMAKS-UHFFFAOYSA-N 2-nitro-5-phenylmethoxybenzaldehyde Chemical compound C1=C(C=O)C([N+](=O)[O-])=CC=C1OCC1=CC=CC=C1 LILVVZJBGYMAKS-UHFFFAOYSA-N 0.000 description 1
WSGYTJNNHPZFKR-UHFFFAOYSA-N 3-hydroxypropanenitrile Chemical compound OCCC#N WSGYTJNNHPZFKR-UHFFFAOYSA-N 0.000 description 1
YEMFHJFNJPXYOE-UHFFFAOYSA-N 3-iodo-1h-pyridin-2-one Chemical compound OC1=NC=CC=C1I YEMFHJFNJPXYOE-UHFFFAOYSA-N 0.000 description 1
NQKIFRSZGVLWSK-UHFFFAOYSA-N 4-iodo-2-methoxy-6-trimethylsilylpyridine-3-carbaldehyde Chemical compound COC1=NC([Si](C)(C)C)=CC(I)=C1C=O NQKIFRSZGVLWSK-UHFFFAOYSA-N 0.000 description 1
241000759905 Camptotheca acuminata Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
241000531785 Rhynochetos jubatus Species 0.000 description 1
238000006859 Swern oxidation reaction Methods 0.000 description 1
MXZQOTDQZBUTHH-UHFFFAOYSA-M [I-].[Mg+]C=C Chemical compound [I-].[Mg+]C=C MXZQOTDQZBUTHH-UHFFFAOYSA-M 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
150000003797 alkaloid derivatives Chemical class 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
244000309464 bull Species 0.000 description 1
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
229910000024 caesium carbonate Inorganic materials 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
CRGRWBQSZSQVIE-UHFFFAOYSA-N diazomethylbenzene Chemical compound [N-]=[N+]=CC1=CC=CC=C1 CRGRWBQSZSQVIE-UHFFFAOYSA-N 0.000 description 1
PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000019256 formaldehyde Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
XJTQJERLRPWUGL-UHFFFAOYSA-N iodomethylbenzene Chemical compound ICC1=CC=CC=C1 XJTQJERLRPWUGL-UHFFFAOYSA-N 0.000 description 1
229910052743 krypton Inorganic materials 0.000 description 1
DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
239000010410 layer Substances 0.000 description 1
UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
IJMWREDHKRHWQI-UHFFFAOYSA-M magnesium;ethene;chloride Chemical compound [Mg+2].[Cl-].[CH-]=C IJMWREDHKRHWQI-UHFFFAOYSA-M 0.000 description 1
239000011702 manganese sulphate Substances 0.000 description 1
235000007079 manganese sulphate Nutrition 0.000 description 1
SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
SCVOEYLBXCPATR-UHFFFAOYSA-L manganese(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O SCVOEYLBXCPATR-UHFFFAOYSA-L 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
229910052754 neon Inorganic materials 0.000 description 1
GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
229910052756 noble gas Inorganic materials 0.000 description 1
238000001668 nucleic acid synthesis Methods 0.000 description 1
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
229910000343 potassium bisulfate Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
229910052704 radon Inorganic materials 0.000 description 1
SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
229910000342 sodium bisulfate Inorganic materials 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
CUGZEDSDRBMZMY-UHFFFAOYSA-N trihydrate;hydrochloride Chemical compound O.O.O.Cl CUGZEDSDRBMZMY-UHFFFAOYSA-N 0.000 description 1
229910052724 xenon Inorganic materials 0.000 description 1
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
- C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
- C07C205/21—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C205/22—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring having one nitro groups bound to the ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/37—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/44—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by —CHO groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/45—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly—bound oxygen atom, not being part of a —CHO group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

NO20033579A 2001-02-21 2003-08-13 Fremgangsmate for syntetisering av camptothecin relaterte forbindelser NO328628B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2001045430		2001-02-21
JP2001309322		2001-10-05
PCT/JP2002/001538 WO2002066416A1 (fr)	2001-02-21	2002-02-21	Procede de synthese de composes se rapportant a la camptothecine (cpt)

Publications (3)

Publication Number	Publication Date
NO20033579D0 NO20033579D0 (no)	2003-08-13
NO20033579L NO20033579L (no)	2003-10-10
NO328628B1 true NO328628B1 (no)	2010-04-12

Family

ID=26609837

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20033579A NO328628B1 (no)	2001-02-21	2003-08-13	Fremgangsmate for syntetisering av camptothecin relaterte forbindelser
NO20093402A NO331656B1 (no)	2001-02-21	2009-11-24	Framgangsmate for syntetisering av camptothesin relaterte forbindelser

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20093402A NO331656B1 (no)	2001-02-21	2009-11-24	Framgangsmate for syntetisering av camptothesin relaterte forbindelser

Country Status (23)

Country	Link
US (2)	US7126000B2 (cs)
EP (1)	EP1378505B1 (cs)
JP (2)	JP4210119B2 (cs)
KR (2)	KR100864692B1 (cs)
CN (1)	CN100408550C (cs)
AR (2)	AR035684A1 (cs)
AU (1)	AU2002237527B2 (cs)
BG (2)	BG108031A (cs)
BR (1)	BR0207470A (cs)
CA (2)	CA2437702C (cs)
CZ (1)	CZ20032470A3 (cs)
EE (1)	EE05361B1 (cs)
HU (1)	HUP0302755A3 (cs)
IL (2)	IL156949A0 (cs)
MX (1)	MXPA03007528A (cs)
NO (2)	NO328628B1 (cs)
NZ (2)	NZ527615A (cs)
PL (2)	PL217238B1 (cs)
RO (2)	RO125158A2 (cs)
RU (1)	RU2308447C2 (cs)
SK (2)	SK288149B6 (cs)
TW (1)	TWI245768B (cs)
WO (1)	WO2002066416A1 (cs)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ299329B6 (cs) *	2003-08-26	2008-06-18	Pliva-Lachema A.S.	Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
CZ299593B6 (cs) *	2003-12-16	2008-09-10	Pliva-Lachema A. S.	Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
JP2008509211A (ja) *	2004-08-09	2008-03-27	シルパ・メディケア・リミテッド	塩酸イリノテカン三水和物の改良された製造方法
NZ554677A (en) *	2004-11-05	2010-08-27	Samyang Corp	Pharmaceutical formulation for increasing solubility of 10-hydroxycamptothecin compounds in non-aqueous polar solvents
WO2006082279A1 (en) *	2005-02-07	2006-08-10	Fermion Oy	Process for the manufacturing of 7-ethyl-10-hydroxy camptothecin
PL1928883T3 (pl)	2005-02-08	2014-03-31	Fermion Oy	Sposób otrzymywania chlorowodorku irynotekanu
CA2591071C (en)	2005-02-08	2014-04-29	Fermion Oy	Process for producing [1,4'] bipiperidinyl-1'-carbonyl chloride or hydrochloride thereof
US8112154B2 (en) *	2005-04-13	2012-02-07	The Cleveland Clinic Foundation	Systems and methods for neuromodulation using pre-recorded waveforms
TWI375678B (en)	2005-06-09	2012-11-01	Yakult Honsha Kk	A method of preparation of a tricyclic ketone
US7608740B2 (en)	2005-08-03	2009-10-27	Avra Laboratories Pvt. Ltd	Method of synthesizing key intermediates for the production of camptothecin derivatives
EP1803725A1 (en) *	2005-12-13	2007-07-04	W.C. Heraeus GmbH	Methods for preparing irinotecan
US9220889B2 (en)	2008-02-11	2015-12-29	Intelect Medical, Inc.	Directional electrode devices with locating features
CN101824038B (zh) *	2009-03-06	2013-08-21	复旦大学	喜树碱及其类似物的制备方法
CA2772330A1 (en)	2009-08-27	2011-03-03	The Cleveland Clinic Foundation	System and method to estimate region of tissue activation
JP5599094B2 (ja) *	2010-05-20	2014-10-01	国立大学法人千葉大学	ニトリル化合物の製造方法
AU2011267853B2 (en)	2010-06-14	2016-12-08	Boston Scientific Neuromodulation Corporation	Programming interface for spinal cord neuromodulation
CA2844081A1 (en)	2011-08-09	2013-02-14	Boston Scientific Neuromodulation Corporation	Remote control for blind clinical trials of electrical stimulation
JP6224106B2 (ja)	2012-08-28	2017-11-01	ボストンサイエンティフィックニューロモデュレイションコーポレイション	リード及び／又は刺激中心に関する臨床効果データの取込み及び可視化
WO2014070290A2 (en)	2012-11-01	2014-05-08	Boston Scientific Neuromodulation Corporation	Systems and methods for voa model generation and use
US8722886B1 (en) *	2012-11-13	2014-05-13	Bionumerik Pharmaceuticals, Inc.	Methods for the total chemical synthesis of enantiomerically-pure 7-(2′-trimethylsilyl)ethyl camptothecin
US9959388B2 (en)	2014-07-24	2018-05-01	Boston Scientific Neuromodulation Corporation	Systems, devices, and methods for providing electrical stimulation therapy feedback
US10272247B2 (en)	2014-07-30	2019-04-30	Boston Scientific Neuromodulation Corporation	Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming
US10265528B2 (en)	2014-07-30	2019-04-23	Boston Scientific Neuromodulation Corporation	Systems and methods for electrical stimulation-related patient population volume analysis and use
EP3204112A1 (en)	2014-10-07	2017-08-16	Boston Scientific Neuromodulation Corporation	Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters
ES2754649T3 (es) *	2014-10-22	2020-04-20	Vivacitas Oncology Inc	Métodos y sistemas para la síntesis del análogo de camptotecina
US10780283B2 (en)	2015-05-26	2020-09-22	Boston Scientific Neuromodulation Corporation	Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
EP3268082B1 (en)	2015-05-26	2019-04-17	Boston Scientific Neuromodulation Corporation	Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
US20160375248A1 (en)	2015-06-29	2016-12-29	Boston Scientific Neuromodulation Corporation	Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects
ES2940303T3 (es)	2015-06-29	2023-05-05	Boston Scient Neuromodulation Corp	Sistemas de selección de parámetros de estimulación por uso de dianas y direccionamiento
US10071249B2 (en)	2015-10-09	2018-09-11	Boston Scientific Neuromodulation Corporation	System and methods for clinical effects mapping for directional stimulation leads
US10716942B2 (en)	2016-04-25	2020-07-21	Boston Scientific Neuromodulation Corporation	System and methods for directional steering of electrical stimulation
WO2017223505A2 (en)	2016-06-24	2017-12-28	Boston Scientific Neuromodulation Corporation	Systems and methods for visual analytics of clinical effects
WO2018044881A1 (en)	2016-09-02	2018-03-08	Boston Scientific Neuromodulation Corporation	Systems and methods for visualizing and directing stimulation of neural elements
US10780282B2 (en)	2016-09-20	2020-09-22	Boston Scientific Neuromodulation Corporation	Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters
EP3493876B1 (en)	2016-10-14	2021-03-17	Boston Scientific Neuromodulation Corporation	Systems for closed-loop determination of stimulation parameter settings for an electrical simulation system
AU2017391436B2 (en)	2017-01-03	2020-06-18	Boston Scientific Neuromodulation Corporation	Systems and methods for selecting MRI-compatible stimulation parameters
US10589104B2 (en)	2017-01-10	2020-03-17	Boston Scientific Neuromodulation Corporation	Systems and methods for creating stimulation programs based on user-defined areas or volumes
US10625082B2 (en)	2017-03-15	2020-04-21	Boston Scientific Neuromodulation Corporation	Visualization of deep brain stimulation efficacy
US11357986B2 (en)	2017-04-03	2022-06-14	Boston Scientific Neuromodulation Corporation	Systems and methods for estimating a volume of activation using a compressed database of threshold values
EP3651849B1 (en)	2017-07-14	2023-05-31	Boston Scientific Neuromodulation Corporation	Estimating clinical effects of electrical stimulation
US10960214B2 (en)	2017-08-15	2021-03-30	Boston Scientific Neuromodulation Corporation	Systems and methods for controlling electrical stimulation using multiple stimulation fields
EP3784332B1 (en)	2018-04-27	2023-04-26	Boston Scientific Neuromodulation Corporation	Systems for visualizing and programming electrical stimulation
JP7295141B2 (ja)	2018-04-27	2023-06-20	ボストンサイエンティフィックニューロモデュレイションコーポレイション	マルチモード電気刺激システム及び製造する及び使用する方法
EP3911660B1 (en) *	2019-01-15	2023-05-10	Laurus Labs Limited	Process for preparation of 2-amino-5-hydroxy propiophenone
US12403315B2 (en)	2021-04-27	2025-09-02	Boston Scientific Neuromodulation Corporation	Systems and methods for automated programming of electrical stimulation
WO2022265977A1 (en)	2021-06-15	2022-12-22	Boston Scientific Neuromodulation Corporation	Methods and systems for estimating neural activation by stimulation using a stimulation system
US12527956B2 (en)	2021-12-09	2026-01-20	Boston Scientific Neuromodulation Corporation	Methods and systems for monitoring or assessing movement disorders or other physiological parameters using a stimulation system
US12471831B2 (en)	2021-12-10	2025-11-18	Boston Scientific Neuromodulation Corporation	Systems and methods for generating and using response maps for electrical stimulation
WO2023167872A1 (en)	2022-03-02	2023-09-07	Boston Scientific Neuromodulation Corporation	Systems and methods for monitoring stimulation drift in an electrical stimulation system
CN118108705A (zh) *	2024-01-29	2024-05-31	浙江工业大学	一种富马酸沃诺拉赞的制备方法
CN120887897A (zh) *	2025-07-30	2025-11-04	德阳悦合生物医药科技有限公司	医药中间体(r)-7-乙基喜树碱的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2061678C1 (ru) *	1992-05-14	1996-06-10	Валерий Павлович Севодин	Способ получения 2-амино-5-нитробензофенона
US5391745A (en)	1992-07-23	1995-02-21	Sloan-Kettering Institute For Cancer Research	Methods of preparation of camptothecin analogs
JPH07101956A (ja) *	1993-10-05	1995-04-18	Tanabe Seiyaku Co Ltd	ヒドロキシカンプトテシン化合物の製法
KR960029336A (ko) *	1995-01-09	1996-08-17	김충환	캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
JPH08225482A (ja) *	1995-02-22	1996-09-03	Dai Ichi Seiyaku Co Ltd	テトラロン関連化合物及びその製法
TW438775B (en)	1995-04-07	2001-06-07	Pharmacia & Upjohn Co Llc	Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
SG50747A1 (en) *	1995-08-02	1998-07-20	Tanabe Seiyaku Co	Comptothecin derivatives
JP3499246B2 (ja)	1995-11-02	2004-02-23	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	カンプトテシン誘導体の製造法
SG103322A1 (en) *	1996-10-30	2004-04-29	Tanabe Seiyaku Co	S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof

2002
- 2002-02-20 AR ARP020100579A patent/AR035684A1/es active IP Right Grant
- 2002-02-20 TW TW091102967A patent/TWI245768B/zh not_active IP Right Cessation
- 2002-02-21 IL IL15694902A patent/IL156949A0/xx unknown
- 2002-02-21 RO ROA200900165A patent/RO125158A2/ro unknown
- 2002-02-21 SK SK5001-2011A patent/SK288149B6/sk not_active IP Right Cessation
- 2002-02-21 RU RU2003128530/04A patent/RU2308447C2/ru not_active IP Right Cessation
- 2002-02-21 EP EP02703874.4A patent/EP1378505B1/en not_active Expired - Lifetime
- 2002-02-21 AU AU2002237527A patent/AU2002237527B2/en not_active Ceased
- 2002-02-21 JP JP2002565934A patent/JP4210119B2/ja not_active Expired - Fee Related
- 2002-02-21 CN CNB028053230A patent/CN100408550C/zh not_active Expired - Fee Related
- 2002-02-21 WO PCT/JP2002/001538 patent/WO2002066416A1/ja not_active Ceased
- 2002-02-21 KR KR1020077030609A patent/KR100864692B1/ko not_active Expired - Fee Related
- 2002-02-21 NZ NZ52761502A patent/NZ527615A/xx not_active IP Right Cessation
- 2002-02-21 MX MXPA03007528A patent/MXPA03007528A/es active IP Right Grant
- 2002-02-21 PL PL399009A patent/PL217238B1/pl unknown
- 2002-02-21 SK SK1147-2003A patent/SK288073B6/sk not_active IP Right Cessation
- 2002-02-21 KR KR1020037010841A patent/KR100858972B1/ko not_active Expired - Fee Related
- 2002-02-21 RO ROA200300695A patent/RO122639B9/ro unknown
- 2002-02-21 US US10/467,987 patent/US7126000B2/en not_active Expired - Lifetime
- 2002-02-21 PL PL363440A patent/PL218065B1/pl unknown
- 2002-02-21 EE EEP200300373A patent/EE05361B1/xx not_active IP Right Cessation
- 2002-02-21 BR BRPI0207470-2A patent/BR0207470A/pt not_active IP Right Cessation
- 2002-02-21 HU HU0302755A patent/HUP0302755A3/hu unknown
- 2002-02-21 CZ CZ20032470A patent/CZ20032470A3/cs unknown
- 2002-02-21 CA CA2437702A patent/CA2437702C/en not_active Expired - Fee Related
- 2002-02-21 CA CA2683768A patent/CA2683768C/en not_active Expired - Fee Related
2003
- 2003-07-15 IL IL156949A patent/IL156949A/en not_active IP Right Cessation
- 2003-07-25 BG BG108031A patent/BG108031A/bg unknown
- 2003-08-13 NO NO20033579A patent/NO328628B1/no not_active IP Right Cessation
- 2003-08-14 NZ NZ534374A patent/NZ534374A/xx not_active IP Right Cessation
2006
- 2006-09-08 US US11/517,621 patent/US7378555B2/en not_active Expired - Lifetime
2008
- 2008-03-28 JP JP2008085358A patent/JP4805967B2/ja not_active Expired - Lifetime
2009
- 2009-11-24 NO NO20093402A patent/NO331656B1/no not_active IP Right Cessation
2011
- 2011-08-11 AR ARP110102927A patent/AR082663A2/es not_active Application Discontinuation
2013
- 2013-04-23 BG BG10111453A patent/BG111453A/en unknown

Also Published As

Publication number	Publication date
BR0207470A (pt)	2008-04-08
CA2683768A1 (en)	2002-08-29
SK288149B6 (sk)	2013-12-02
PL218065B1 (pl)	2014-10-31
WO2002066416A1 (fr)	2002-08-29
IL156949A (en)	2009-09-01
CZ20032470A3 (cs)	2004-02-18
CN1492851A (zh)	2004-04-28
BG108031A (bg)	2005-04-30
SK288073B6 (sk)	2013-05-03
JP2008273952A (ja)	2008-11-13
NZ534374A (en)	2004-12-24
RO122639B1 (ro)	2009-10-30
HUP0302755A2 (hu)	2003-12-29
PL399009A1 (pl)	2012-09-10
EE05361B1 (et)	2010-12-15
MXPA03007528A (es)	2003-12-11
JP4805967B2 (ja)	2011-11-02
US7378555B2 (en)	2008-05-27
US20070010674A1 (en)	2007-01-11
EP1378505A4 (en)	2006-09-27
HUP0302755A3 (en)	2008-03-28
EP1378505A1 (en)	2004-01-07
CA2437702C (en)	2010-04-06
IL156949A0 (en)	2004-02-08
CA2437702A1 (en)	2002-08-29
NO20093402L (no)	2003-10-10
PL217238B1 (pl)	2014-06-30
TWI245768B (en)	2005-12-21
SK11472003A3 (sk)	2004-03-02
RO125158A2 (ro)	2010-01-29
CN100408550C (zh)	2008-08-06
AR035684A1 (es)	2004-06-23
KR100864692B1 (ko)	2008-10-23
EE200300373A (et)	2003-10-15
NO20033579L (no)	2003-10-10
NO331656B1 (no)	2012-02-13
US7126000B2 (en)	2006-10-24
BG111453A (en)	2013-09-30
JPWO2002066416A1 (ja)	2004-09-24
CA2683768C (en)	2013-05-28
NO20033579D0 (no)	2003-08-13
KR100858972B1 (ko)	2008-09-17
RO122639B9 (ro)	2014-03-28
AR082663A2 (es)	2012-12-26
JP4210119B2 (ja)	2009-01-14
KR20080012383A (ko)	2008-02-11
NZ527615A (en)	2004-12-24
PL363440A1 (en)	2004-11-15
RU2003128530A (ru)	2005-03-27
AU2002237527B2 (en)	2007-01-04
KR20030077631A (ko)	2003-10-01
EP1378505B1 (en)	2014-11-05
RU2308447C2 (ru)	2007-10-20
US20040106830A1 (en)	2004-06-03

Legal Events

Date	Code	Title	Description
2015-09-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO328628B1 (no)	2010-04-12	Fremgangsmate for syntetisering av camptothecin relaterte forbindelser
JP5762624B2 (ja)	2015-08-12	安定な７員環ラクトンを含むカンプトテシン化合物、それらの製造方法及び使用
US5446047A (en)	1995-08-29	Camptothecin analogues
TWI330187B (en)	2010-09-11	Synthesis of silyl camptothecins and silyl homocamptothecins
Ashok et al.	2016	Solvent-free microwave assisted synthesis of morpholine–piperidine–pyrrolidine annulated quinoline-naphthyl based chalcones and their antimicrobial activity
Mbala et al.	2011	Investigation towards an efficient synthesis of benzo [g] isoquinoline-1, 5, 10 (2H)-triones
CA2591071C (en)	2014-04-29	Process for producing [1,4'] bipiperidinyl-1'-carbonyl chloride or hydrochloride thereof
Fang et al.	2014	Synthesis of 6, 7-Dihydrodibenzo [b, j] phenanthroline Derivatives by Pfitzinger Condensation of Isatin and Cyclic Diketones
OHTA et al.	1994	Synthetic approaches to 3-amino-1, 4-naphthoquinone-2-carboxylic acid derivatives and photochemical synthesis of novel 1, 4, 5, 10-tetrahydro-5, 10-dioxo-2H-naphth [2, 3-d][1, 3] oxazine derivatives
Moskalenko et al.	2009	Synthesis of N-arylmethyl-3-azabicyclo [3.3. 1] nonan-9-ones.
CN116396272B (zh)	2025-06-20	一种2,5-二氢吡咯烷类衍生物及消旋尼古丁的制备方法
Ghoneim et al.	2021	Synthesis of bis chalcones, and transformation into bis heterocyclic compounds with expected antimicrobial activity
JP5863846B2 (ja)	2016-02-17	イリノテカンの製造方法
Hu et al.	2009	Facile synthesis of novel tacrine analogues
CN117186089A (zh)	2023-12-08	一种四氢咔啉衍生物的制备方法
Wang et al.	2006	An improved synthesis of reduced 9-arylacridine-1, 8-diones from 3-amino-5, 5-dimethylcyclohex-2-enone, arylaldehydes and 1, 3-dicarbonyl compounds in aqueous medium
KR101471943B1 (ko)	2014-12-11	7-히드록시-3'',4'',5-트리메톡시플라본의 제조방법
WO2006129781A1 (ja)	2006-12-07	ジベンズオキセピン誘導体の製造方法
Chantegrel et al.	1984	Synthesis of 3‐alkenyl‐4‐oxo‐6, 7‐dihydro‐1H‐pyrano [4, 3‐c] pyrazole derivatives
Sagitullina et al.	2005	Novel Approach to Synthesis of meta-Terphenyls.
Scheffler et al.	2000	Carbohydrate α-oxoketene N, O-ketals in the synthesis of dihydroquinolines
Mustafa et al.	1992	(9-(Pyridazinyl-4)-4-azafluorenes and spiro compounds with 4-azafluorene and indeno [1, 2-c] pyridazine (4h-5, 6-dihydro-1, 2-diazepine) fragments
HK1231871A1 (en)	2017-12-29	A process for the preparation of compound and synthetic intermediates thereof
HK1205105A1 (zh)	2015-12-11	制备化合物的方法及其合成中间体
JPH0670029B2 (ja)	1994-09-07	新規ビスベンゾフラン誘導体およびその製造法